Table 1.
Disease | Intervention | Model | Main Findings | Reference |
---|---|---|---|---|
Cancer cachexia | Salidroside | Mice with C26 and LLC | Decreased mTORC1 in muscle | Chen et al., 2016 [97] |
C2C12 treated with TNF-⍺ | Decreased mTORC1 in myotubes | |||
Raptor KO mice | Mice with LLC and C26 | Decreased mTORC1 activity Increased autophagic flux |
Geremia et al., 2022 [98] | |
IL-6 receptor Ab | ApcMin/+ mice | Decreased mTORC1 activity Increased AMPK activity |
White et al., 2011 [72] | |
Aerobic exercise Rapamycin |
C26-bearing mice and colon carcinoma patients | Loss of body weight Decreased autophagic flux |
Pigna et al., 2016 [100] | |
Rapamycin | C2C12 cells treated with conditioned media from C26 cells | Induced myotube atrophy Blockage of autophagic flux |
||
Everolimus or Temsirolimus (Rapalog) | 20 patients with renal cell carcinoma or pancreatic neuroendocrine tumour | Decreased muscle quantity, muscle mass and skeletal muscle area. | Gyawali et al., 2016 [101] | |
Everolimus | 410 patients with advanced pancreatic neuroendocrine tumors | Loss of body weight and reduced appetite. | Yao et al., 2011 [102] | |
Everolimus with endocrine therapy, aromatase inhibitor | 724 female patients with ER-positive breast cancer | Decreased body weight and reduced appetite. | Baselga et al., 2012 [103] | |
Everolimus | 302 patients with advanced, nonfunctional, well-differentiated lung or gastrointestinal neuroendocrine tumors | Decreased appetite. | Yao et al., 2016 [104] | |
Temsirolimus | 162 patients with relapsed or refractory MCL | Hess et al., 2009 [105] | ||
Nivolumab Everolimus |
821 patients with advanced clear-cell renal-cell carcinoma | Motzer et al., 2015 [106] | ||
Sarcopenia | Rapamycin | Male mice expressing LC3-GFP | Reactivation of autophagy prevented satellite cells senescence. | Garcia-Prat et al., 2016 [80] |
Rapalog RAD001 | Old Male Sprague-Dawley rats (27 months) | Increased mTORC1 activation | Joseph et al., 2019 [110] | |
Exercise | 21-month-old Wistar rats | Increased autophagy via downregulating mTORC1 pathway. | Zeng et al., 2020 [119] | |
Calorie restriction | Middle-aged Male Sprague-Dawley rats (20 months old) | Decreased mTORC1 activity | Chen et al., 2019 [120] | |
Calorie restriction and resveratrol |
Male FBN 25-month-old rats | Enhanced autophagy by inhibition of mTORC1 pathway | Dutta et al., 2014 [121] | |
Calorie restriction and dietary resveratrol |
Middle age to old age mice (14 months old to 30 months old) | Both dietary interventions prevent aging process through mTORC1 | Barger et al., 2008 [122] | |
Spermidine and exercise | D-galactose-induced aging rats with skeletal muscle atrophy | Increased autophagy | Fan et al., 2017 [123] | |
Spermidine | 8-week-old specific pathogen-free male C57/BL mice | Induced muscle atrophy and enhanced autophagy in MuSCs. | Zhang et al., 2018 [124] | |
Testosterone therapy and resistance exercise | 18 aged men (Ages 65–75 years) | Improve aging muscle performance and muscle mass via mTORC1 | Gharahdaghi et al., 2019 [125] |